Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 5/20 | 0.36 |
| ▸ | CDK2 | P24941 | 4/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 4/20 | 0.33 |
| ▸ | SRC | P12931 | 4/20 | 0.33 |
| ▸ | CSNK1D | P48730 | 5/20 | 0.33 |
| ▸ | CSNK1E | P49674 | 5/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.32 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.32 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
| ▸ | CDK7 | P50613 | 1/20 | 0.31 |
| ▸ | CDK9 | P50750 | 1/20 | 0.31 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30012905 | 0.99 | GSK3B (0.36) | GSK3BCDK2EGLN1ABL1SRC | |
| SCHEMBL23508063 | 0.90 | GSK3B (0.36) | GSK3BCDK2ABL1SRC | |
| SCHEMBL23508197 | 0.89 | CDK12 (0.40) | CDK2CSNK1DCSNK1ECDK1CDK7 | |
| SCHEMBL23508152 | 0.87 | EGLN1 (0.34) | CDK2EGLN1ABL1SRCCSNK1D | |
| SCHEMBL30013417 | 0.87 | EGLN1 (0.34) | CDK2EGLN1ABL1SRCCSNK1D | |
| SCHEMBL23497421 | 0.85 | CSNK1D (0.35) | CDK2EGLN1ABL1SRCCSNK1D | |
| SCHEMBL30012969 | 0.84 | PKM (0.43) | GSK3B | |
| SCHEMBL23497457 | 0.84 | PKM (0.43) | GSK3B | |
| SCHEMBL23497710 | 0.83 | EGLN1 (0.36) | GSK3BCDK2EGLN1ABL1SRC | |
| SCHEMBL23508366 | 0.81 | CSNK1E (0.46) | CDK2CSNK1DCSNK1ECDK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230117034-A1 | PYRAZOLOTRIAZINES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-20 | — | — | US | disclosed |
| WO-2021116178-A1 | PYRAZOLOTRIAZINES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230117034-A1 | PYRAZOLOTRIAZINES | BRCA1, TPX2, CCND2 | GSK3B 3545/4885CDK2 43/4885EGLN1 2442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.